| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant and award revenue | 789 | 1,085 | 1,159 | 2,169 |
| Research and development | 6,111 | 6,070 | 5,824 | 6,394 |
| General and administrative | 3,463 | 3,426 | 3,111 | 2,619 |
| Impairment expense | NaN | 5,412 | NaN | NaN |
| Total operating expenses | 9,574 | 14,908 | 8,935 | 9,013 |
| Operating loss | -8,785 | -13,823 | -7,776 | -6,844 |
| Interest income | 60 | 131 | 90 | 108 |
| Interest expense | 5,559 | 4,834 | 4,346 | 3,808 |
| Change in fair value of the convertible loan | -101,062 | -105,772 | -14,643 | -5,751 |
| Total other income (expense), net | -106,561 | -110,475 | -18,899 | -9,451 |
| Net loss | -115,346 | -124,298 | -26,675 | -16,295 |
| Basic EPS | -3.16 | -3.419 | -0.74 | -0.45 |
| Diluted EPS | -3.16 | -3.43 | -0.74 | -0.45 |
| Basic Average Shares | 36,530,284 | 36,352,446 | 36,226,285 | 36,193,479 |
| Diluted Average Shares | 36,530,284 | 36,239,253* | 36,226,285 | 36,193,479 |
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)